Latest Headlines

Latest Headlines

J&J's Janssen teams up with Intrexon for diabetes pill

Platform specialist Intrexon has teamed up with Johnson & Johnson's Janssen for a research collaboration to use its oral delivery system in therapies designed to treat Type 2 diabetes, obesity or metabolic disorders. The terms of the deal remain undisclosed.

Intrexon partner AmpliPhi raises $13M for antibiotic R&D

AmpliPhi BioSciences has lined up $13 million in private placement cash, selling stock and warrants to fund its pipeline of treatments for drug-resistant bacterial infections.

Developer of oral versions of biologic therapies to be purchased by Intrexon

Biotech player Intrexon has signed up to acquire Belgium's ActoGeniX for $60 million. The new addition is a developer of oral meds as an alternative to injectable biologics. Currently, biologic therapies cannot withstand the rigors of the acid in the stomach, so oral versions of the new-era drugs are lacking.

Intrexon takes a $60M flyer on a synthetic biology startup

Billionaire R.J. Kirk's Intrexon has signed a $60 million deal to acquire ActoGeniX, a Belgian biotech at work on oral drugs designed to generate therapeutic proteins and peptides from within the body.

Intrexon and Ziopharm buy into CAR-T in $100M deal

Partners Intrexon and Ziopharm are cutting in on the fervor over a new class of immunotherapies for cancer, striking a deal with the University of Texas' MD Anderson Cancer Center.

Ziopharm, Intrexon tackle CAR-T in expanded partnership

Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology is expanding its R&D collaboration with Intrexon to include the personalized immuno-oncology technology.

Intrexon bets $26M on stem cells, teams up with troubled OvaScience

Intrexon, a Maryland biotech backed by billionaire RJ Kirk, has agreed to snap up San Diego regenerative medicine outfit for $26 million, and the company inked a separate agreement with OvaScience to combine their technology platforms.

Biotech billionaire inks ocular pipeline pact with India's Sun

Biotech billionaire Randal "RJ" Kirk's synthetic biology company Intrexon has announced plans to partner with India's Sun Pharmaceutical on a pipeline of new drugs for ocular diseases, starting with dry age-related macular degeneration.

Upsized Intrexon IPO delivers another blockbuster success for billionaire Kirk

The sizzling market for biotech IPOs will end one day, but it won't be today. RJ Kirk's synthetic biology company Intrexon made its debut on Wall Street today and shares quickly zoomed up past the $22 mark, leaving the company with a hefty market value of more than $2 billion and its founder with another fortune.

Is biotech billionaire Kirk's Intrexon worth $1.4B?

Germantown, MD-based Intrexon, a synthetic biology outfit led by billionaire Randal Kirk, aims to sell 8.3 million shares at a proposed range of $14 to $16 per share.